Jierui Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jierui Xu has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Henry Walch
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
23 shared publications - Nikolaus Schultz
Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
23 shared publications - Walid Chatila
Memorial Sloan Kettering Cancer Center
23 shared publications - Umesh Bhanot
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
17 shared publications - Andrew L. Kung
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
16 shared publications - Andrika D. Thomas
Memorial Sloan Kettering Cancer Center 1 New York, NY
16 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S5 from Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer
Figure S1: Quality-control parameters and sensitivity analyses of CLDN18.2 microenvironmental and pathway changes Figure S2: Additional sensitivity survival analyses of the YCC cohort and CheckMate 649 trial Figure S3: Features of cellular neighbourhoods and correlation with progression-free survival Figure S4: Supplementary analyses to digital spatial profiling Figure S5: B/plasma cell enrichment scores across the tumor-stroma interface
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S5 from Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer
Figure S1: Quality-control parameters and sensitivity analyses of CLDN18.2 microenvironmental and pathway changes Figure S2: Additional sensitivity survival analyses of the YCC cohort and CheckMate 649 trial Figure S3: Features of cellular neighbourhoods and correlation with progression-free survival Figure S4: Supplementary analyses to digital spatial profiling Figure S5: B/plasma cell enrichment scores across the tumor-stroma interface
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-4 from Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer
Supplementary Tables 1-4 from Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-4 from Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer
Supplementary Tables 1-4 from Spatial Organization of Tumor-Infiltrating B Cells Informs Immune Checkpoint Inhibitor Response in Claudin 18.2–Expressing Gastric Cancer
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Optimization efforts to procure patient tumors, establish PDX tumor models and cryopreserve PDX tumor specimen.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Optimization efforts to procure patient tumors, establish PDX tumor models and cryopreserve PDX tumor specimen.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Comparative analysis of mutations in patient source tumors and corresponding PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Comparative analysis of mutations in patient source tumors and corresponding PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Validation of a EPB41L2::RAF1 gene fusion in an osteosarcoma PDX model.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Validation of a EPB41L2::RAF1 gene fusion in an osteosarcoma PDX model.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Evaluation of the EPB41L2::RAF1 gene fusion as an oncogenic driver and therapeutic target in osteosarcoma PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Evaluation of the EPB41L2::RAF1 gene fusion as an oncogenic driver and therapeutic target in osteosarcoma PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of sarcoma patient tumors and corresponding PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of sarcoma patient tumors and corresponding PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of osteosarcoma patient tumors and corresponding PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of osteosarcoma patient tumors and corresponding PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of neuroblastoma patient tumors and corresponding PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of neuroblastoma patient tumors and corresponding PDX models.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of Other Tumor cohort and corresponding PDX models.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies
Unsupervised hierarchical clustering of Other Tumor cohort and corresponding PDX models.